Celmatix
Celmatix's Resolve platform uses multi-omic and clinical big data to map ovarian reserve and design non-hormonal candidates against ovarian ageing, and Hungarian pharma Gedeon Richter has acquired Celmatix's women's-health drug-discovery portfolio spanning fertility and endometriosis programs.
- Country
- United States
Ovarian longevity R&D
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| FemTech biotech & women's health | regenerative-personalized | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.